OBJECTIVE： To investigate the effects of Silibinin capsules combined with routine therapy on serum oxidative injury and liver function of patients with alcoholic liver disease （ALD） complicated with early liver fibrosis. METHODS： The patients with ALD complicated with early liver fibrosis selected from our hospital during Apr. 2013-Jan. 2015 were divided into control group and study group according to random number table， with 38 cases in each group. Control group received routine symptomatic treatment [temperance， oral administration of Inosine tablets （0.4 g/times， bid）， vitamin and microelement supplementation， etc.]. Study group was additionally given Silibinin capsule （70 mg/time， bid） orally， for consecutive 48 weeks， on the basis of control group. The clinical efficacies and the incidence of ADR were compared between 2 groups. The changes of serum oxidative injury indexes （SOD， MDA）， liver fibrosis indexes [laminin （LN）， hyaluronic acid （HA）， type Ⅳ collagen （Ⅳ-C）， type Ⅲ procollagen （PC Ⅲ）] and liver function indexes （ALT， AST） were recorded before and after treatment. RESULTS： Before treatment， there was no statistical significance in baseline information between 2 groups （P＞0.05）. After treatment， total response rate of study was significantly higher than that of control group （P＜0.05）， but there was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. Compared with before treatment， serum levels of MDA， liver fibrosis indexes and liver function indexes in 2 groups were decreased significantly （P＜0.05）， while SOD levels were increased significantly （P＜0.05）； the improvement of study group was more significant than control group （P＜0.05）. CONCLUSIONS： Silibinin capsules combined with routine treatment can enhance clinical efficacy of ALD patients with early liver fibrosis， mainly manifesting as improving oxidative stress， regulating liver function and inhibiting the development of liver fibrosis.